Bladder Pain Syndrome Clinical Trial
Official title:
Functional Magnetic Resonance Imaging Findings and Symptoms in Bladder Pain Syndrome: A Descriptive Study
The goal of this observational study is to investigate the relationship between functional magnetic resonance imaging (fMRI) findings of the brain and symptom presentation in patients with bladder pain syndrome (BPS). The main questions it aims to answer are: 1. To explore the distribution characteristics of fMRI imaging and possible target lesions in the patient population. 2. To provide appropriate clues and evidence for etiological exploration and therapeutic targeting of BPS. Participants will undergo fMRI as well as other routine laboratory tests and queries.
Status | Recruiting |
Enrollment | 120 |
Est. completion date | December 31, 2026 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria for BPS group: 1. Be 18 years of age or older and female; 2. Be diagnosed with BPS (persistent or recurrent pain in the bladder area accompanied by at least one other symptom, such as increased pain when the bladder is full, and frequent urination during the day and/or at night, according to the current diagnostic criteria and clinical guidelines, without any of the conditions listed in the "Exclusion Criteria" below); 3. Persistence of symptoms for more than 6 months; 4. Visual analogue scale (VAS) of pain = 4; 5. O'Leary-Sant Interstitial Cystitis questionnaire (IC-Q) score of 12 or more, with pain and nocturia domain scores >2; 6. Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) >13; 7. No history of cystoscopy within 2 years. Exclusion Criteria for BPS group: 1. With proliferative cystoplasty or previous surgery or any pharmacological and non-pharmacological treatment for BPS; 2. Pregnant or lactating women; 3. Contraindications to MRI; 4. Average urine output less than 40 ml or more than 400 ml; 5. Haematuria (more than 1+ in urine dipstick test); 6. Evidence of current urinary tract infection at the time of recruitment; 7. Tuberculosis of the genitourinary system or cancer of the bladder or uroepithelial cancer; 8. Recurrent urinary tract infection; 9. History of hysterectomy, mid-urethral sling, pelvic organ prolapse repair, vaginal delivery or caesarean section, prostate surgery or treatment within 6 months; 10. History of neurological disease such as cerebral infarction, multiple sclerosis, or Parkinson's disease; 11. Reliance on catheterisation; including clean intermittent catheterisation or indwelling catheterisation; 12. Planned rehabilitation therapy affecting bladder function. Inclusion Criteria for Control group: 1. Be 18 years of age or older and female; 2. With symptoms of bladder pain (defined as persistent or recurrent pain in the bladder area accompanied by at least one other symptom, such as increased pain when the bladder is full, and frequent urination during the day and/or at night) according to current diagnostic criteria and clinical guidelines; 3. Have a pain visual analogue scale (VAS) = 4; 4. Evidence of a current urinary tract infection; 5. Pelvic Pain and Urgency/Frequency Patient Symptom Scale (PUF) >13; 6. No history of cystoscopy within 2 years. Exclusion Criteria for Control group: 1. With proliferative cystoplasty or previous surgery or any pharmacological and non-pharmacological treatment for BPS; 2. Pregnant or lactating women; 3. Contraindications to MRI; 4. Average urine output less than 40 ml or more than 400 ml; 5. Tuberculosis of the genitourinary system or cancer of the bladder or uroepithelial cancer; 6. History of hysterectomy, mid-urethral sling, pelvic organ prolapse repair, vaginal delivery or caesarean section, prostate surgery or treatment within 6 months; 7. History of neurological disease such as cerebral infarction, multiple sclerosis, or Parkinson's disease; 8. Dependence on catheterisation; including clean intermittent catheterisation or indwelling catheterisation; 9. Planned rehabilitation that affects bladder function. |
Country | Name | City | State |
---|---|---|---|
China | Renji Hospital, Shanghai Jiao Tong University School of Medicine | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
RenJi Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | fMRI findings | The fMRI is acquired using a Siemens 3.0T MRI scanner. BOLD functional images are scanned using an echo planar imaging (EPI) sequence. The scanning parameters are: TR=2s, matrix size of 64*64, number of layers=30, layer thickness=3.75*3.75*4.5mm, and bottom-up interval scanning. A total of 540 whole brain functional images are acquired.
The relevant data acquired from fMRI should undergo the following pre-processing before generating findings: (1) data format conversion; (2) temporal layer correction; (3) head movement correction; (4) normalization; (5) smoothing |
1 day (fMRI is performed once upon the recruitment of the study subject.) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04313972 -
IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone
|
Phase 4 | |
Completed |
NCT03282318 -
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
|
Phase 2 | |
Terminated |
NCT02591199 -
Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04401176 -
Bladder Instillations Versus Onabotulinumtoxin A for Treatment of Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04001244 -
Translational Research in Pelvic Pain
|
||
Suspended |
NCT04450316 -
Low-dose Naltrexone for Bladder Pain Syndrome
|
Phase 2 | |
Completed |
NCT04010513 -
Hypnosis for Bladder Pain Syndrome
|
N/A | |
Recruiting |
NCT05518864 -
GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis (GETSBI Study)
|
Phase 4 | |
Active, not recruiting |
NCT05414305 -
The Female Microbiome in Patients Undergoing Bladder Instillation Therapy
|
Phase 2 | |
Withdrawn |
NCT03027076 -
Microbiome of Urologic Chronic Pelvic Pain Syndrome
|
N/A | |
Terminated |
NCT01879930 -
Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective Study
|
Phase 4 | |
Recruiting |
NCT05155384 -
Biopsychosocial and Conventional Approach in Bladder Pain Syndrome
|
N/A | |
Recruiting |
NCT05737121 -
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
|
Phase 2 | |
Recruiting |
NCT05699551 -
Supervised Exercise as a Therapeutic Strategy for Interstitial Cystitis/Bladder Pain Syndrome
|
N/A | |
Recruiting |
NCT06299683 -
Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment
|
N/A | |
Completed |
NCT04821882 -
Intravesical Injection of Dextrose to Improve Lower Urinary Tract Symptoms Caused by Chronic Cystitis
|
N/A | |
Completed |
NCT04208087 -
PK and Safety of SI-722 in IC/BPS
|
Phase 1/Phase 2 | |
Recruiting |
NCT05740007 -
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
|
Phase 2 | |
Recruiting |
NCT03076762 -
Comparative Study Suburothelial and Trigonal Botulinum Toxin A Injection in Treatment of Interstitial Cystitis
|
Phase 2 | |
Active, not recruiting |
NCT04789135 -
Evaluation of Response to Use of Intravesical Ozone Gas in Interstitial Cystitis /Bladder Pain Syndrome
|
Phase 2 |